Sort   by:  
 Page size 
ProteomicsTumor-selective effects of active RAS inhibition in pancreatic ductal adenocarcinoma
Broad-spectrum RAS inhibition holds the potential to benefit roughly a quarter of human cancer patients whose tumors are driven by RAS mutations. RMC-7977 is a highly selective inhibitor of the active GTP-bound forms of KRAS, HRAS, and NRAS, with affinity for both mutant and wild type (WT) variants....
ORGANISM(S): Mus musculus (Mouse) 
2024-03-15 | PXD047878 | Pride
Rmc-7977 Kpc Ras Pdac 
Genomics
Whole exome sequencing of parental and RMC-7977-resistant NRAS-mutated melanoma PDX-derived cell lines
PRJNA1466267 | ENA
Genomics
Whole exome sequencing of RMC-7977 resistant cell lines derived from mouse melanoma OSUMMER.1 or OSUMMER.10 cells
PRJNA1465302 | ENA
ProteomicsThe temporal effect of RMC-7977 treatment on the PANC-1 cell total proteome
KRAS-driven pancreatic ductal adenocarcinoma (PDAC) is dependent on nutrient scavenging pathways to fuel the metabolic demands of proliferation. While acute KRAS loss results in downregulated macropinocytosis, we observed that this downregulation is transient and returns to basal levels in the absen...
ORGANISM(S): Homo sapiens (Human) 
2026-06-25 | PXD066616 | Pride
Ras inhibitors Resistance Global proteomics Pancreatic cancer 
TranscriptomicsRAS(ON) multi-selective inhibition drives anti-tumor immunity in preclinical models of NRAS-mutant melanoma
Targeted therapies for NRAS-mutant melanoma remain an unmet clinical need. Here, we demonstrate that RMC-7977, a preclinical RAS(ON) multi-selective inhibitor respresentative of the investigational agent daraxonrasib (RMC-6236), elicits potent anti-tumor immune responses across several NRAS-mutant m...
ORGANISM(S): Mus musculus 
2025-10-22 | GSE300712 | GEO
TranscriptomicsSingle-cell RNAseq of from murine pancreas tumor (FPC)
Oncogenic KRAS drives pancreatic ductal adenocarcinoma (PDAC), yet resistance to RAS antagonists limits benefit. We deployed two complementary preclinical PDAC models, including a degron-regulated KRASG12D-dependent transplantation model, and a KrasG12V-driven PDAC mouse model treated with the RAS(O...
ORGANISM(S): Mus musculus 
2026-09-07 | GSE315796 | GEO
TranscriptomicsMulti-selective RAS(ON) Inhibition Targets Oncogenic RAS Mutations and Overcomes RAS/MAPK-Mediated Resistance to FLT3 and BCL2 Inhibitors in Acute Myeloid Leukemia
Aberrant activation of the RAS/MAPK signaling limits the clinical efficacy of several targeted therapies in acute myeloid leukemia (AML). In FLT3-mutant AML, the selection of clones harboring heterogeneous RAS mutations drives resistance to FLT3 inhibitors (FLT3i). RAS activation is also associated ...
ORGANISM(S): Homo sapiens 
2025-07-04 | GSE301645 | GEO
UnknownMulti-selective RAS(ON) Inhibition Targets Oncogenic RAS Mutations and Overcomes RAS/MAPK-Mediated Resistance to FLT3 and BCL2 Inhibitors in Acute Myeloid Leukemia.
Not available
S-EPMC12259086 | biostudies-literature
UnknownTumour-selective activity of RAS-GTP inhibition in pancreatic cancer.
Not available
S-EPMC11111406 | biostudies-literature
UnknownConcurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy.
Not available
S-EPMC11111408 | biostudies-literature
Sort   by:  
 Page size